Interstitial lung disease in polymyositis and dermatomyositis

Michito Hirakata, Sonoko Nagai

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Interstitial lung disease (ILD) is common in patients with polymyositis (PM) and dermatomyositis (DM), and is a major cause of morbidity. Although its cause is unknown, it is known to be closely associated with autoimmune disorders. Its manifestation has been found to be quite heterogeneous, as demonstrated by the differences among PM/DM patients in their immunologic profiles and histopathologic findings, which suggest variations in immunopathogenetic mechanisms. We review the clinicopathologic and immunologic findings in ILD associated with PM/DM, and discuss recent advances in classification, autoantibodies, and treatment. The most critical issues are to clarify the immunopathogenesis of severe forms of ILD, such as rapidly progressive ILD associated with amyopathic DM, and to establish the most appropriate therapy. (C) 2000 Lippincott Williams and Wilkins, Inc.

Original languageEnglish
Pages (from-to)501-508
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume12
Issue number6
DOIs
Publication statusPublished - 2000

Fingerprint

Dermatomyositis
Interstitial Lung Diseases
Autoantibodies
Morbidity
Therapeutics

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Interstitial lung disease in polymyositis and dermatomyositis. / Hirakata, Michito; Nagai, Sonoko.

In: Current Opinion in Rheumatology, Vol. 12, No. 6, 2000, p. 501-508.

Research output: Contribution to journalArticle

@article{41efb79e8f9b4c2dbcf4b9ed0829824d,
title = "Interstitial lung disease in polymyositis and dermatomyositis",
abstract = "Interstitial lung disease (ILD) is common in patients with polymyositis (PM) and dermatomyositis (DM), and is a major cause of morbidity. Although its cause is unknown, it is known to be closely associated with autoimmune disorders. Its manifestation has been found to be quite heterogeneous, as demonstrated by the differences among PM/DM patients in their immunologic profiles and histopathologic findings, which suggest variations in immunopathogenetic mechanisms. We review the clinicopathologic and immunologic findings in ILD associated with PM/DM, and discuss recent advances in classification, autoantibodies, and treatment. The most critical issues are to clarify the immunopathogenesis of severe forms of ILD, such as rapidly progressive ILD associated with amyopathic DM, and to establish the most appropriate therapy. (C) 2000 Lippincott Williams and Wilkins, Inc.",
author = "Michito Hirakata and Sonoko Nagai",
year = "2000",
doi = "10.1097/00002281-200011000-00005",
language = "English",
volume = "12",
pages = "501--508",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Interstitial lung disease in polymyositis and dermatomyositis

AU - Hirakata, Michito

AU - Nagai, Sonoko

PY - 2000

Y1 - 2000

N2 - Interstitial lung disease (ILD) is common in patients with polymyositis (PM) and dermatomyositis (DM), and is a major cause of morbidity. Although its cause is unknown, it is known to be closely associated with autoimmune disorders. Its manifestation has been found to be quite heterogeneous, as demonstrated by the differences among PM/DM patients in their immunologic profiles and histopathologic findings, which suggest variations in immunopathogenetic mechanisms. We review the clinicopathologic and immunologic findings in ILD associated with PM/DM, and discuss recent advances in classification, autoantibodies, and treatment. The most critical issues are to clarify the immunopathogenesis of severe forms of ILD, such as rapidly progressive ILD associated with amyopathic DM, and to establish the most appropriate therapy. (C) 2000 Lippincott Williams and Wilkins, Inc.

AB - Interstitial lung disease (ILD) is common in patients with polymyositis (PM) and dermatomyositis (DM), and is a major cause of morbidity. Although its cause is unknown, it is known to be closely associated with autoimmune disorders. Its manifestation has been found to be quite heterogeneous, as demonstrated by the differences among PM/DM patients in their immunologic profiles and histopathologic findings, which suggest variations in immunopathogenetic mechanisms. We review the clinicopathologic and immunologic findings in ILD associated with PM/DM, and discuss recent advances in classification, autoantibodies, and treatment. The most critical issues are to clarify the immunopathogenesis of severe forms of ILD, such as rapidly progressive ILD associated with amyopathic DM, and to establish the most appropriate therapy. (C) 2000 Lippincott Williams and Wilkins, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033735604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033735604&partnerID=8YFLogxK

U2 - 10.1097/00002281-200011000-00005

DO - 10.1097/00002281-200011000-00005

M3 - Article

C2 - 11092199

AN - SCOPUS:0033735604

VL - 12

SP - 501

EP - 508

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 6

ER -